Healthcare

Immuron is a Melbourne-based biopharmaceutical company working with orally delivered polyclonal antibodies derived from bovine colostrum. Its commercial product, Travelan, is an over-the-counter supplement sold to reduce the risk of travellers' diarrhoea. Australia is the core market, with the United States and Canada the …

Immutep is a Sydney-headquartered biotechnology company built around Lymphocyte Activation Gene-3, or LAG-3, a target it has worked on for more than two decades through its FrenchSubsidiaryImmutep S.A.S. Its lead candidate, eftilagimod alfa (efti), is a soluble LAG-3 protein the company describes as a …

TrivarX is still at the stage where preparation itself is a catalyst. The healthcare stock rose 6.67% to AUD 0.016 on 11 August 2026, while the company's recent work has centred on moving Stabl-Im from program planning toward a defined Phase 1 clinical pathway.

For Neurotech International, regulatory clearance matters more than a green day on the screen. The stock rose 7.14% to AUD 0.015 as of 11 August 2026, but the more consequential development came in July, when NTI164 cleared a US FDA step that opens the …

Careteq is smaller after selling Embedded Health Solutions, but that is precisely why the market now has a clearer question to answer: what can the remaining healthtech platform become on its own? The stock was quoted at AUD 0.013 as of 11 August 2026, …

For Acrux, the most important recent development did not come from the share price screen; it came from a licensing agreement. The specialty pharmaceutical company was quoted at AUD 0.012 as of 11 August 2026, up 9.09%. That modest price sits alongside a potentially …

PolyNovo has continued expanding its wound-care technology platform while navigating a period whereBusinessgrowth and share market performance have moved in different directions. The company’s focus remains on commercialising NovoSorb products, expanding its US presence and progressing additional clinical and regulatory opportunities.